Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$72.56 USD
-0.95 (-1.29%)
Updated Jul 19, 2024 04:00 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GILD 72.56 -0.95(-1.29%)
Will GILD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Other News for GILD
Gilead, EJAF announce five-year extension of Radian partnership
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
UN urges Gilead to "make history" with game-changing HIV drug
Here are Big Pharma’s leading blockbuster makers
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)